Skip to content
Bored Studies
RecruitingAccepts healthy volunteersEarly Phase 1

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

Hugh Taylor · NCT05343572

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–40 · Women only
Healthy volunteers
Accepted
Study type
Interventional · Early Phase 1
Target enrollment
90
US sites recruiting
1
Study start
November 1, 2023
Record last updated
November 12, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).

Being studied: Plerixafor

Conditions: Asherman Syndrome; Atrophic Endometrium; Recurrent Implantation Failure

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Healthy, non pregnant females
  • ages ≥18 and ≤40 years old at time of enrollment
  • with either AS, AE, or RIF
  • For AS: surgical history of intrauterine trauma/infection, hypo/amenorrhea, intra-uterine adhesions
  • for AE: US documentation of persistent, \<6mm endometrial thickness
  • for RIF: failure to achieve a clinical pregnancy after transfer of at least four good-quality embryos in a minimum of three fresh or frozen cycles in a woman under 40 years and currently being treated at Yale Fertility Clinic

Exclusion Criteria

  • Presence of hydrosalpinx (diagnosed by radiographic or ultrasound imaging)
  • Endometriosis (diagnosed by previous surgery,)
  • Diminished ovarian reserve (AMH\<1ng/ml or follicle stimulating hormone (FSH)>10)
  • History of genital tuberculosis or any ultrasound evidence of congenital uterine anomaly
  • Submucous or intracavitary fibroid, polyps
  • Currently pregnant
  • Personal history of thrombophilia or sickle cell disease
  • Inability to provide informed consent

Recruiting US locations

Study contacts (from the official record)

  • Hugh S Taylor, MD · (203)-785-6949 · hugh.taylor@yale.edu
  • Michele Frank, BSN · (203)-785-6949 · Michele.Frank@yale.edu
All healthy volunteers studies in Connecticut →
Bone Marrow Derived Stem Cells Mobilization for Treatment of… (NCT05343572) | Bored Studies